Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Astellas Pharma Inc.    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Tokyo Stock Exchange
03/27/2020 03/30/2020 03/31/2020 04/01/2020 04/02/2020 Date
1724.5 1722 1671 1606.5 1590 Last
10300700 10053400 9682000 6414800 7272300 Volume
+8.09% -0.14% -2.96% -3.86% -1.03% Change
Financials (JPY)
Sales 2020 1 275 B
EBIT 2020 257 B
Net income 2020 204 B
Finance 2020 458 B
Yield 2020 2,57%
Sales 2021 1 278 B
EBIT 2021 264 B
Net income 2021 208 B
Finance 2021 579 B
Yield 2021 2,73%
P/E ratio 2020 14,1x
P/E ratio 2021 14,1x
EV / Sales2020 1,96x
EV / Sales2021 1,86x
Capitalization 2 955 B
More Financials
Company
Astellas Pharma specializes in the research, development, manufacturing and marketing of pharmaceutical products. Products are especially for immune diseases, infectious diseases, skin diseases, cancer and urologic disorders. Net sales are distributed geographically as follows: Japan (31.2%), Asia... 
Sector
Pharmaceuticals
Calendar
05/20Earnings Release
More about the company
Surperformance© ratings of Astellas Pharma Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on ASTELLAS PHARMA INC.
03/30ASTELLAS PHARMA : Launches its Corporate Website's Science Section
PU
03/30ASTELLAS PHARMA INC. : Ex-dividend day for final dividend
FA
03/24CytomX Therapeutics and Astellas Announce Strategic Collaboration to Develop ..
AQ
03/23ASTELLAS PHARMA : CytomX Therapeutics and Astellas Announce Strategic Collaborat..
PU
03/18ASTELLAS PHARMA : Gifu University and Astellas establish a Research Course on Ph..
AQ
02/27ASTELLAS PHARMA : Notice Regarding the Performance-linked Stock Compensation Sch..
PU
02/20Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation fo..
AQ
02/19ASTELLAS PHARMA : and Seattle Genetics Receive FDA Breakthrough Therapy Designat..
PU
02/12ASTELLAS PHARMA : XTANDI Demonstrates Significant Improvement in Overall Surviva..
AQ
02/11SEATTLE GENETICS : and Astellas Announce Updated Results from Phase 1b/2 Trial o..
AQ
02/06ASTELLAS PHARMA : Announces Management Structure
AQ
02/03ASTELLAS PHARMA : Announces Completion of Acquisition of Own Shares, and Cancell..
PU
01/31ASTELLAS PHARMA : Submits Supplemental New Drug Application for Approval of Evre..
AQ
01/31Astellas Pharma keeps profit forecast as prostate cancer drug sales rise
RE
01/31ASTELLAS PHARMA : Will Renew Its Corporate Website's Innovation Section
PU
More news
News in other languages on ASTELLAS PHARMA INC.
03/30ASTELLAS PHARMA INC. : Ex-dividend day for final dividend
03/05Les Bourses asiatiques terminent en nette hausse, imitant Wall Street
03/05Tokyo finit en hausse, dopée par Wall Street
03/04Tokyo en nette hausse, dans le sillage de Wall Street
02/25Tokyo dévisse de 3,3% en clôture, le coronavirus inquiète
More news
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 2 129,17  JPY
Last Close Price 1 590,00  JPY
Spread / Highest target 82,4%
Spread / Average Target 33,9%
Spread / Lowest Target -5,66%
EPS Revisions
Managers
NameTitle
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Chikashi Takeda Senior Executive Officer & Head-Finance
Naoki Okamura Representative Director & Vice President
Tomokazu Fujisawa Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC.-1.73%28 860
JOHNSON & JOHNSON-8.72%345 705
ROCHE HOLDING AG2.77%277 060
MERCK & CO., INC-16.16%195 141
NOVARTIS-11.15%187 703
PFIZER, INC.-14.14%181 075